Fundz

Innovein reported raising $2.55 Million in an initial SEC Form D filing, from an offering of $11.9 Million

PRIVATEFeb 06, 2023$2.5M of $11.9M raised

Amount Raised

$2.55 Million

$2.55 Million sold, per SEC Form D (first sale Jan 25, 2023)

Round Type

Seed

Santa RosaHealthcare

Quick answer

Innovein raised $2.55 Million in a Seed round, dated January 25, 2023. Innovein is based in Santa Rosa, California, United States.

How much did Innovein raise?
Innovein raised $2.55 Million in a Seed round on January 25, 2023.
What does Innovein do?
NOTICE: Please visit our website for any current job opportunities.
Where is Innovein based and how big is it?
Innovein is based in Santa Rosa, California, United States.

Source: Fundz verified event record.

Who else raised in Healthcare around the same time

Companies in the same sectors as Innovein that raised within 45 days of this round, from Fundz verified event records.

  • Pearl SurgiCenter raised $39K (Seed) on March 10, 2023.
  • CirculoGene Theranostics, LLC raised $2M (Seed) on March 9, 2023.
  • QurAlis raised $88M (Series B) on March 9, 2023.
  • Expect Fitness raised $95K (Pre-Seed) on March 8, 2023.
  • Guided Clinical Solutions raised $3M (Seed) on March 7, 2023.
  • Presa Solutions raised $110K (Pre-Seed) on March 7, 2023.

Who to call at Innovein, and when

A new round usually means Innovein is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Innovein raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Innovein, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Innovein. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Innovein

Location

1745 Copperhill Parkway

Santa Rosa, California, United States

About

NOTICE: Please visit our website for any current job opportunities. Innovein has not and will not post job opportunities on LinkedIn. Over 10% of the US/EU suffers from bad valves in the veins of legs and advanced vein disease, with no option for valve replacement. Innovein, a Y Combinator and VC backed medical device company, addresses this unmet medical need with a first-in-class replacement valve for veins. Innovein has been awarded by Forbes, the Medical Device and Diagnostic Industry, MIT (CHIEF), and many others. In aggregate, the founding team of three has invented and brought over 15 medical devices to market, selling over $3B. They are addressing the multi-billion dollar unmet need of vein disease and successfully oversubscribed target financing.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Innovein raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Innovein's next move

See what Strategic adds

Innovein raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.